Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global Chronic Renal Failure Therapeutic Market: By Product: Antihypertensive therapeutics, Antianaemia Therapeutics, Others; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis, EMR’s Key Indicators for Demand; Competitive Landscape; Industry Events and Developments
Global Chronic Renal Failure Therapeutic Market Outlook
The global chronic renal failure therapeutic market size is expected to grow at a CAGR of 6% in the forecast period of 2022-2027. The industry has witnessed a substantial growth in the recent years across the world in both developing and developed countries.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Properties and Applications
Chronic kidney failure or chronic renal failure involves the loss of kidney functions over a prolonged period of time as opposed to acute renal failure. Stage 6 is for patients with a glomerular filtration rate of less than 15 mL per minute. For their renal failure, dialysis intervention is required.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry can be divided based on segments like the product types and regions. The industry can be broadly categorised on the basis of product into:
- Antihypertensive Therapeutics
- Antianaemia Therapeutics
- Others
The EMR report looks into the regional markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
Cardiovascular and metabolic conditions are the major risk factors for chronic renal failure. The increased prevalence of these risk factors leads to a significant increase in chronic renal disease incidence. Most of the market for this disorder is from the geriatric population in the United States, Europe, and Asia. Throughout the forecast period, the growing prevalence of chronic renal failure will consequently increase the growth prospects of the industry for chronic renal failure therapeutic. Developing novel inhibitors of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) will also accelerate the industry growth for chronic renal failure therapies. For patients without haemodialysis, oral administration of HIF-PH drugs is preferable. Such factors raise the demand for these medications, leading to the expansion of the global therapeutic market for chronic renal failure.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global chronic renal failure therapeutic market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Amgen Inc. (NASDAQ: AMGN)
- AstraZeneca Plc
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Pfizer Inc.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter's Five Forces.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Product, Region |
| Breakup by Product | Antihypertensive therapeutics, Antianaemia Therapeutics, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Amgen Inc. (NASDAQ: AMGN), AstraZeneca Plc (LON: AZN), F. Hoffmann-La Roche Ltd. (SWX: ROG), Bayer AG (ETR: BAYN), Pfizer Inc. (NYSE: PFE), Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Chronic Renal Failure Therapeutic Market Analysis
8.1 Key Industry Highlights
8.2 Global Chronic Renal Failure Therapeutic Historical Market (2017-2021)
8.3 Global Chronic Renal Failure Therapeutic Market Forecast (2022-2027)
8.4 Global Chronic Renal Failure Therapeutic Market by Product
8.4.1 Antihypertensive Therapeutics
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Antianemia Therapeutics
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Others
8.5 Global Chronic Renal Failure Therapeutic Market by Region
8.5.1 Market Share
8.5.1.1 North America
8.5.1.2 Europe
8.5.1.3 Asia Pacific
8.5.1.4 Latin America
8.5.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 EMR’s Key Indicators for Demand
10.4 EMR’s Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Amgen Inc.
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 AstraZeneca PLC
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Pfizer Inc.
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 F. Hoffmann-La Roche Ltd
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Bayer AG
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Others
12 Industry Events and Developments
List of Figures and Tables
1. Global Chronic Renal Failure Therapeutic Market: Key Industry Highlights, 2017 and 2027
2. Global Chronic Renal Failure Therapeutic Historical Market: Breakup by Product (USD Million), 2017-2021
3. Global Chronic Renal Failure Therapeutic Market Forecast: Breakup by Product (USD Million), 2022-2027
4. Global Chronic Renal Failure Therapeutic Historical Market: Breakup by Region (USD Million), 2017-2021
5. Global Chronic Renal Failure Therapeutic Market Forecast: Breakup by Region (USD Million), 2022-2027
6. North America Chronic Renal Failure Therapeutic Historical Market: Breakup by Country (USD Million), 2017-2021
7. North America Chronic Renal Failure Therapeutic Market Forecast: Breakup by Country (USD Million), 2022-2027
8. Europe Chronic Renal Failure Therapeutic Historical Market: Breakup by Country (USD Million), 2017-2021
9. Europe Chronic Renal Failure Therapeutic Market Forecast: Breakup by Country (USD Million), 2022-2027
10. Asia Pacific Chronic Renal Failure Therapeutic Historical Market: Breakup by Country (USD Million), 2017-2021
11. Asia Pacific Chronic Renal Failure Therapeutic Market Forecast: Breakup by Country (USD Million), 2022-2027
12. Latin America Chronic Renal Failure Therapeutic Historical Market: Breakup by Country (USD Million), 2017-2021
13. Latin America Chronic Renal Failure Therapeutic Market Forecast: Breakup by Country (USD Million), 2022-2027
14. Middle East and Africa Chronic Renal Failure Therapeutic Historical Market: Breakup by Country (USD Million), 2017-2021
15. Middle East and Africa Chronic Renal Failure Therapeutic Market Forecast: Breakup by Country (USD Million), 2022-2027
16. Global Chronic Renal Failure Therapeutic Market Structure
Key Questions Answered in the Report
The global chronic renal failure therapeutic market is projected to grow at a CAGR of 6% between 2021 and 2026.
The major drivers of the industry, such as the growing incidences of chronic renal failure, changing lifestyle and consumption patterns, increasing geriatric population, and the growing technological advancements, are expected to aid the market growth.
The key market trends guiding the growth of the industry include the development of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors and the growing R&D activities.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Antihypertensive and antianaemia therapeutics, among others, are the leading products of chronic renal failure therapeutic in the industry.
The major players in the industry are Amgen Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Bayer AG, and Pfizer Inc., among others.
Analyst Review
The global chronic renal failure therapeutic market is being driven by the rising prevalence of cardiovascular disorders, which leads to chronic renal failure. Aided by the development of novel oral HIF-PH inhibitors, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 6%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on products, the industry can be segmented into antihypertensive, and antianaemia therapeutics, among others. The major regional markets for chronic renal failure therapeutic are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Amgen Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Bayer AG, and Pfizer Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global PD-1 and PD-L1 inhibitors market attained a value of USD 30.3 billion in 2021, driven by the rising incidences of cancer. Aided by the growing geriatric population and favourable government...
The global biosurgery market attained a value of more than USD 13.4 billion in 2021, driven by the prevalence of different biosurgeries. Aided by advancements in healthcare structure, the market is ex...
The global albumin market attained a value of USD 5.3 billion in 2021, driven by the rising benefits of HSA on commercial and therapeutic applications. Aided by advancements in nanotechnology for drug...
The global hydrophobic interaction chromatography market attained a value of over USD 320.3 million in 2021, driven by the increased demand for monoclonal antibodies. Aided by the rising investments i...
The global peptide therapeutics market attained a value of 33.58 billion in 2021, driven by the increasing prevalence of cancer. Aided by the increasing clinical trials and the growing FDA approval of...
NEWSLETTER